The clinical utility of immune checkpoint inhibitors is limited by immune-related adverse events (irAEs); understanding the mechanisms of irAE development is thus crucial. A study reports that IL-17A-expressing CD4+ T cells were elevated at irAE onset and provides proof of concept for using IL-17A blockade to improve irAEs in two patients.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Ribas, A. & Wolchok, J. D. Science 359, 1350–1355 (2018).
Sharpe, A. H. & Pauken, K. E. Nat. Rev. Immunol. 18, 153–167 (2018).
Postow, M. A., Sidlow, R. & Hellmann, M. D. N. Engl. J. Med. 378, 158–168 (2018).
Darnell, E. P., Mooradian, M. J., Baruch, E. N., Yilmaz, M. & Reynolds, K. L. Curr. Oncol. Rep. 22, 39 (2020).
Hua, C. et al. JAMA Dermatol. 152, 45–51 (2016).
Quaglino, P. et al. Ann. Oncol. 21, 409–414 (2010).
Eggermont, A. M. M. et al. AMA Oncol. 6, 519–527 (2020).
NCCN Guidelines: Management of Immunotherapy Related Toxicities. National Cancer Comprehensive Guidelines (2024).
Bai, X. et al. Clin. Cancer Res. 27, 5993–6000 (2021).
Martins, F. et al. Lancet Oncol. 20, e54–e64 (2019).
Dimitriou, F. et al. Nat. Cancer https://doi.org/10.1038/s43018-024-00810-4 (2024).
Hailemichael, Y. et al. Cancer Cell 40, 509–523.e6 (2022).
Fa’ak, F. et al. J. Immunother. Cancer 11, e006814 (2023).
Neelapu, S. S. et al. Nat. Rev. Clin. Oncol. 15, 47–62 (2018).
Thomas, M. F. et al. Nat. Med. 30, 1349–1362 (2024).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
G.M.B. has sponsored research agreements through her institution with Olink Proteomics, Teiko Bio, InterVenn Biosciences and Palleon Pharmaceuticals. She served on advisory boards for Iovance, Merck, Moderna, Nektar Therapeutics, Novartis and Ankyra Therapeutics. She consults for Merck, InterVenn Biosciences, Iovance and Ankyra Therapeutics. She holds equity in Ankyra Therapeutics.
Rights and permissions
About this article
Cite this article
Sierra-Davidson, K., Boland, G.M. Targeting IL-17A to combat immune-related adverse events. Nat Cancer 5, 1289–1291 (2024). https://doi.org/10.1038/s43018-024-00804-2
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s43018-024-00804-2
